Jardiance phase 3 exercise ability studies in chronic heart failure fail to meet primary endpoint

Jardiance phase 3 exercise ability studies in chronic heart failure fail to meet primary endpoint

Source: 
Pharmaceutical Business Review
snippet: 


Jardiance, a type 2 diabetes drug developed by Boehringer Ingelheim and Eli Lilly and Company (Lilly), failed to meet the primary endpoint of two late-stage exercise ability trials in chronic heart failure.